NCT05707910View on ClinicalTrials.gov

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Malignant Tumor
Interventions
BIOLOGICAL

EBV immunological agent

Low-dose group:2\*10\^7 Medium-dose group:5\*10\^7 High-dose group:2\*10\^8

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER